NEW YORK, March 02, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aetna Inc. securities (NYSE:AET) from August 15, 2016 through January 20, 2017, inclusive (the “Class Period”) of the important March 27, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Aetna investors under the federal securities laws.
To join the Aetna class action, go to http://rosenlegal.com/cases-1039.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aetna and its senior executives attempted to leverage Aetna’s participation in the Public Exchanges for favorable treatment from regulators regarding the Humana acquisition; (2) Aetna threatened to limit its participation in public health insurance exchanges if the Department of Justice (“DOJ”) attempted to block the merger; (3) Aetna did not withdraw from certain public health insurance exchanges for business reasons as Defendants claimed, but to follow through on its threat of leaving the marketplace once the DOJ filed suit and to improve its litigation position; (4) Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and (5) as a result of the foregoing, Defendants’ statements about Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1039.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
First Western Ship Transits Strait of Hormuz Since Iran War Began
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 



